Gilead Archives

In Depth 18 Jul 2024

Lenacapavir: Can Gilead’s drug end the HIV pandemic?

Discover more about Gilead’s lenacapavir, which recently demonstrated 100% efficacy for HIV prevention in a phase 3 trial.

July 18, 2024 - 7 minutesmins - By Willow Shah-Neville

News and Trends 20 Jul 2023

Seven pharma companies form alliance to prepare for future pandemics

Seven pharmaceutical companies have established the INTREPID Alliance with the goal of accelerating progress in discovery and development of new antiviral treatments for future pandemics. The seven companies are AbbVie, Amgen, Gilead, Johnson & Johnson, Novartis, Roche and Takeda. The INTREPID alliance creation is in support of the 100 Days Mission, which seeks to have […]

July 20, 2023 - 5 minutesmins - By Jim Cornall

Kintor Pharmaceutical drug gets positive results for breast cancer

News and Trends 19 Aug 2022

Gilead to acquire remaining worldwide rights of breast cancer drug, Trodelvy

All of Everest Medicine’s development and commercialization rights for a breast cancer drug called Trodelvy have been transferred to American biopharma Gilead Sciences Inc. The transfer of the antibody drug, sacituzumab govitecan treatment, will apply to Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia. In China mainland and Singapore, Trodelvy is […]

August 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 4 Mar 2021

Galapagos and Gilead Soldier On After Inflammatory Disease Flops

Clinical and regulatory setbacks have left the star biotech duo Gilead and Galapagos smarting and their stock value bruised in recent months. Yet the pair claim to be well capitalized to weather the storm and determined to do so together. The two companies forged an unusual blockbuster agreement in 2019, valued at around €4.5B ($5.1B), […]

March 4, 2021 - 4 minutesmins - By Victor Kotsev

News and Trends 5 Oct 2020

Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection

The recent EU and Japan approvals of the rheumatoid arthritis drug filgotinib contrast with the FDA’s rejection in August. What does this signal for Galapagos, Gilead, and other biotechs working in inflammatory disease? For Galapagos and Gilead, it’s been a rollercoaster few months. In August, the FDA decided against approving their drug filgotinib for treating […]

October 5, 2020 - 5 minutesmins - By Jonathan Smith

News and Trends 8 Jul 2020

Remdesivir Becomes the First Covid-19 Treatment Approved in Europe

Remdesivir has received a one-year conditional marketing authorization from the European Commission due to the urgency of the Covid-19 pandemic, which has infected at least 2.5 million people in Europe, and killed more than 500,000. The intravenous drug, manufactured by US pharma company Gilead Sciences, is intended for adults and children over the age of […]

July 8, 2020 - 3 minutesmins - By Victor Kotsev

gilead galapagos arthritis pulmonary fibrosis

News and Trends 15 Jul 2019

Gilead Pays Billions for Access to Galapagos’ Pipeline

Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for pulmonary fibrosis. As part of the deal, Gilead will pay Galapagos €3.5B ($3.95B) upfront, with a further €1B ($1.1B) in equity investment. In return, Gilead gets […]

July 15, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Jun 2019

Belgian and US Biotechs Team up to Reduce CAR T Side Effects

The diagnostics company Biocartis is collaborating with Kite Pharma to monitor the progress of CAR T-cell therapies in patients to better manage side effects. CAR T-cell therapies have revolutionized the way we treat cancer. Instead of giving the patient a classical drug, companies can inject them with living, genetically engineered cells that kill cancer cells. […]

June 3, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 3 Jan 2019

Austrian Biopharma Reaches First HIV Vaccine Milestone

Hookipa Pharma has reached its first milestone in a partnership deal with US-based CAR T pioneers Gilead Sciences to develop an HIV vaccine using the Austrian company’s arenavirus-based technology. Hookipa’s lead candidate is a prophylactic vaccine for cytomegalovirus, a common infection that can be dangerous in people with weak immune systems, such as those with […]

January 3, 2019 - 2 minutesmins - By Helen Albert

News and Trends 5 Jul 2017

Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in […]

July 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 14 Feb 2017

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is trying to prove that its candidate bictegravir is better. GSK and Gilead have announced they will present detailed data backing their candidates for a dual HIV therapy. The battlefield will be the Annual Conference on Retroviruses […]

February 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Dec 2016

Galapagos gets another Milestone Payment from Gilead

Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can this partnership beat out its many competitors? Galapagos is one of the few billion-euro biotechs in Europe, boasting top-level partnerships with AbbVie for cystic fibrosis and MorphoSys for inflammatory diseases. The company now has news […]

December 9, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Gilead

Lenacapavir: Can Gilead’s drug end the HIV pandemic?

Seven pharma companies form alliance to prepare for future pandemics

Gilead to acquire remaining worldwide rights of breast cancer drug, Trodelvy

Galapagos and Gilead Soldier On After Inflammatory Disease Flops

Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection

Remdesivir Becomes the First Covid-19 Treatment Approved in Europe

Gilead Pays Billions for Access to Galapagos’ Pipeline

Belgian and US Biotechs Team up to Reduce CAR T Side Effects

Austrian Biopharma Reaches First HIV Vaccine Milestone

Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year

Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best

Galapagos gets another Milestone Payment from Gilead

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!